The cytochrome P450 3A subfamily (CYP3A) members, such CYP3A4, CYP3A5, and CYP3A7, are the most abundant P450 enzymes expressed in human liver and intestine and are responsible for metabolizing >50% of drugs. Significant variations in CYP3A activity and gene expression have been found in liver during development, with infants and young children having different ability to metabolize many drugs than adults. Particularly, CYP3A4 and CYP3A7 exhibit profound reciprocal patterns of gene expression with a developmental switch after birth. However, the mechanisms governing the ontogenic expression of the CYP3A genes during development are unknown. Our long- term research goal is to unravel the mechanisms that control drug metabolism during development. The objective of this proposal is to identify the mechanisms controlling the ontogenic expression of the Cyp3a genes in livers during postnatal development by using mouse as a model. Our central hypothesis is that the ontogenic expression patterns of the Cyp3a genes in mouse liver are controlled by transcription factors which change epigenetic modifications at the target chromatin, and place the Cyp3a genes in distinct nuclear positions, allowing the Cyp3a genes to be turned on or off at different developmental stages. To test this hypothesis, we propose to pursue the following specific aims: (1) to establish profiles of histone modifications around the Cyp3a genes in liver cells at different ages;(2) to define chromatin condensation, nuclear positions, and associated histone modifications of the Cyp3a genes in hepatocyte nuclei at different ages;and (3) to examine the roles of the transcription factors in controlling ontogenic expression of the Cyp3a genes during liver maturation. We have assembled a multidisciplinary team and have all the techniques and mouse models ready for the proposed studies, which will help to ensure a successful completion of the proposed studies. If we prove our hypothesis is correct, the proposed study will identify transcription factors which control the ontogenic expression of the Cyp3a genes through epigenetic mechanisms. It would add greatly to our fundamental knowledge of developmental regulation of gene expression in liver development. This knowledge is particularly novel for drug metabolizing enzymes, because the areas of epigenetics and gene positioning have not received much attention with respect to the ontogeny of genes involved in drug biotransformation. Establishment of this fundamental knowledge is essential for understanding difference of drug responses between pediatric and adult patients and is important for establishing pharmaco-epigenomics based on inter-individual variation of epigenomes in personalized medicine.

Public Health Relevance

The proposed research is important for establishing the general mechanisms controlling ontogenic gene expression of drug metabolizing enzymes in liver during early postnatal ages. This fundamental knowledge will help us to understand why children have different ability to metabolize drugs than adults.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
7R01GM087376-04
Application #
8496961
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
2010-02-01
Project End
2015-01-31
Budget Start
2012-08-23
Budget End
2013-01-31
Support Year
4
Fiscal Year
2012
Total Cost
$251,578
Indirect Cost
$90,946
Name
University of Connecticut
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
614209054
City
Storrs-Mansfield
State
CT
Country
United States
Zip Code
06269
Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248
Pope, Chad; Mishra, Shashank; Russell, Joshua et al. (2017) Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver Diseases. Diseases 5:
Pope, Chad; Piekos, Stephanie C; Chen, Liming et al. (2017) The role of H19, a long non-coding RNA, in mouse liver postnatal maturation. PLoS One 12:e0187557
Piekos, Stephanie; Pope, Chad; Ferrara, Austin et al. (2017) Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life. Curr Pharmacol Rep 3:1-9
Yan, Liang; Wang, Yiting; Liu, Jingyang et al. (2017) Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin. Mol Pharmacol 92:113-123
Prabhakar, Bindu; Zhong, Xiao-Bo; Rasmussen, Theodore P (2017) Exploiting Long Noncoding RNAs as Pharmacological Targets to Modulate Epigenetic Diseases. Yale J Biol Med 90:73-86
Tien, Yun-Chen; Piekos, Stephanie C; Pope, Chad et al. (2017) Phenobarbital Treatment at a Neonatal Age Results in Decreased Efficacy of Omeprazole in Adult Mice. Drug Metab Dispos 45:330-335
Peng, Lai; Piekos, Stephanie; Guo, Grace L et al. (2016) Role of farnesoid X receptor in establishment of ontogeny of phase-I drug metabolizing enzyme genes in mouse liver. Acta Pharm Sin B 6:453-459
Wang, Pengcheng; Pradhan, Komal; Zhong, Xiao-Bo et al. (2016) Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 6:384-392
Tracy, Timothy S; Chaudhry, Amarjit S; Prasad, Bhagwat et al. (2016) Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug Metab Dispos 44:343-51

Showing the most recent 10 out of 24 publications